Galderma Secures Canadian Deal for NEMLUVIO, Expanding Access to…

Event summary

Galderma completed negotiations with the pCPA for NEMLUVIO (nemolizumab) for moderate-to-severe atopic dermatitis and prurigo nodularis in Canada.
NEMLUVIO is the first approved monoclonal antibody targeting IL-31 receptor alpha, addressing itch and inflammation in both conditions.
The deal follows positive recommendations from Canada's Drug Agency and INESSS in early 2026.
NEMLUVIO is indicated for patients aged 12+ with moderate-to-severe AD and adults with moderate-to-severe PN not controlled by topical therapies.

The big picture

Galderma's deal with the pCPA marks a strategic milestone in expanding access to NEMLUVIO, a novel treatment for chronic skin conditions. The approval process in Canada, involving multiple regulatory bodies, underscores the growing recognition of NEMLUVIO's efficacy in addressing unmet needs in dermatology. This deal could set a precedent for similar negotiations in other regions, reinforcing Galderma's leadership in the dermatology sector.

What we're watching

Market Expansion: Whether Galderma can replicate this success in other markets, given the positive regulatory momentum in Canada.
Patient Adoption: The pace at which NEMLUVIO gains traction among Canadian patients with moderate-to-severe AD and PN.
Competitive Dynamics: How this deal positions Galderma against competitors in the dermatology space, particularly in the biologic treatments segment.